Metabolic bone diseases in sickle cell anemia patients and evaluation of associated factors

Basit Öğe Kaydı
dc.authoridOzsan Yilmaz, Muge/0000-0001-8346-8941
dc.contributor.authorEskiocak, Ozge
dc.contributor.authorYilmaz, Muge Ozsan
dc.contributor.authorIlhan, Gul
dc.date.accessioned2024-09-18T20:57:00Z
dc.date.available2024-09-18T20:57:00Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Metabolic or non-metabolic many bone diseases can be distinguished in sickle cell anemia. Patients with sickle cell anemia have a high risk of osteopenia and osteoporosis. The aim of this study is to reveal bone mineral density abnormalities and related factors in patients with sickle cell anemia. Methods: A total of 70 patients with sickle cell anemia were retrospectively included in our study. Complete blood count (CBC) parameters, serum creatinine, lactate dehydrogenase (LDH), total bilirubin, direct bilirubin, uric acid, calcium, phosphorus, parathormone, alkaline phosphatase, 25 (OH) vitamin D, ferritin, C reactive protein (CRP) and calculated bone mineral densitometry measurements by Dual-Energy X-ray Absorptiometry (DEXA) were assessed and recorded to the statistics program. We diagnosed osteopenia and osteoporosis according to World Health Organization (WHO) criteria. To determine the status of avascular necrosis and bone fracture, we examined x-ray and magnetic resonance imaging reports and epicrisis reports of patients from the records. Results: The average age was 30.01 +/- 8.64 years. Eighteen (26.5%) of the 68 patients whose Z-score was evaluated by DEXA had bone mass below the expected age-related range according to the Z score, while 50 (73.5%) had bone mass within the expected age-related range. Of the patients whose T score was evaluated by DEXA, 46.8% were normal (n=29), 45.1% were osteopenic (n=28) and 8.1% were osteoporotic (n=5). Conclusions: Patients with sickle cell anemia are at increased risk for osteoporosis, osteopenia, and osteomalacia. Bone health should be emphasized in these patients.en_US
dc.identifier.endpage494en_US
dc.identifier.issn0002-9629
dc.identifier.issn1538-2990
dc.identifier.issue6en_US
dc.identifier.pmid34256033en_US
dc.identifier.scopus2-s2.0-85122301872en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage490en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12235
dc.identifier.volume363en_US
dc.identifier.wosWOS:000925144600010en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofAmerican Journal of The Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSickle cell anemiaen_US
dc.subjectOsteopeniaen_US
dc.subjectOsteoporosisen_US
dc.subjectBone mineral densityen_US
dc.titleMetabolic bone diseases in sickle cell anemia patients and evaluation of associated factorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu